Last reviewed · How we verify

T3 - High dose of BI 655130

Boehringer Ingelheim · Phase 1 active Small molecule Quality 15/100

T3 - High dose of BI 655130 is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development.

At a glance

Generic nameT3 - High dose of BI 655130
SponsorBoehringer Ingelheim
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about T3 - High dose of BI 655130

What is T3 - High dose of BI 655130?

T3 - High dose of BI 655130 is a Small molecule drug developed by Boehringer Ingelheim.

Who makes T3 - High dose of BI 655130?

T3 - High dose of BI 655130 is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

What development phase is T3 - High dose of BI 655130 in?

T3 - High dose of BI 655130 is in Phase 1.

What are the side effects of T3 - High dose of BI 655130?

Common side effects of T3 - High dose of BI 655130 include Headache, Acne, Injection site erythema, Abdominal discomfort, Nasopharyngitis, Throat irritation.

Related